Honeywell & Recipharm to manufacture net-zero inhalers
Electronics manufacturer Honeywell has entered into a commercial partnership with pharmaceutical manufacturer Recipharm, to develop sustainable pressurised metered dose inhalers (pMDIs). These will be built using Honeywell’s near-zero global warming potential (GWP) propellant, to lower the impact on the environment.
Manufacturing medical devices
Founded in 1906, Honeywell International Inc. is a Fortune 100 company headquartered in Charlotte, North Carolina. The company focuses on manufacturing electronics for many industries, from aerospace to medical devices.
An estimated 384m people suffer from chronic obstructive pulmonary disease (COPD), while another 262m live with asthma. To manage these conditions, many people use pressurised metered dose inhalers. pMDIs use hydrofluoroalkanes (HFAs) as propellants and while life-saving, they deplete the ozone layer in a similar way to hairspray.
However, the Honeywell Solstice® Air is a hydrofluoroolefin (HFO) propellant in clinical development, for use in pMDIs that:
- Is non-flammable
- Non-ozone-depleting
- Has 99.9% less global warming potential compared to HFAs
Honeywell is dedicated to carbon neutrality in its operations and facilities by 2035 and the company has invested US$1bn in research and development for its Solstice technology.
An investment in sustainable manufacturing
Laura Reinhard, Vice President and General Manager of Honeywell Foam and Industrial Products is pleased that the collaboration with Recipharm will increase use of near-zero GWP propellant used in pMDIs.
“This will help reduce the environmental impact of the life-saving medical treatments patients need, without sacrificing performance,” she says. “Honeywell is making great strides to offer patients who rely on pMDIs a lower greenhouse gas solution to meet their medical needs.
“Honeywell’s Solstice HFO technology plays an important role in helping the pharmaceutical industry meet its sustainability goals while supporting essential care for respiratory patients around the world. Our partnership with Recipharm is a significant milestone in providing the market with a lower greenhouse gas solution for use in pressurised metered dose inhalers.”
As the first CDMO to partner with Honeywell for use of Solstice Air, Chris Hirst, President of Recipharm’s Advanced Delivery Systems business unit, is proud that this collaboration will significantly accelerate customers development of low greenhouse gas pMDIs.
“Our collaboration is supported by Recipharm’s investment in manufacturing with HFO-1234ze(E) cGMP at our Holmes Chapel, United Kingdom site and the further development of the Bespak® valve range to ensure the required product performance.”
*************************************************
For more insights into Manufacturing - check out the latest edition of Manufacturing Magazine and be sure to follow us on LinkedIn & Twitter.
Other magazines that may be of interest - Healthcare Digital.
*********************************************
BizClik is a global provider of B2B digital media platforms that cover 'Executive Communities' for CEO's, CFO's, CMO's, Sustainability Leaders, Procurement & Supply Chain Leaders, Technology & AI Leaders, Cyber Leaders, FinTech & InsurTech Leaders as well as covering industries such as Manufacturing, Mining, Energy, EV, Construction, Healthcare + Food & Drink.
BizClik, based in London, Dubai & New York offers services such as Content Creation, Advertising & Sponsorship Solutions, Webinars & Events.
